Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 9Unknown 3Active not recruiting 3Withdrawn 1Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER_GOV 1OTHER 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Carcinoma, Hepatocellular 4Recurrence 3Pancreatic Neoplasms 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hematologic Neoplasms 3Colorectal Neoplasms 3Burkitt Lymphoma 3Stomach Neoplasms 2Nasopharyngeal Carcinoma 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lung Neoplasms 2Leukemia, Prolymphocytic, B-Cell 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid 2Leukemia, B-Cell 2Glioma 2Esophageal Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumor 1Simpson-Golabi-Behmel syndrome 1Sarcoma, Synovial 1Prostatic Neoplasms 1Pleural Effusion, Malignant 1Ovarian Neoplasms 1

Interventions

Cyclophosphamide 16fludarabine 12Rituximab 4Antigens, CD19 4Lenalidomide 3Immunotherapy, Adoptive 3Etoposide 3orelabrutinib 2Nivolumab 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Methotrexate 2zanubrutinib 1relmacabtagene autoleucel 1prednylidene 1obinutuzumab 1merphos 1ixazomib 1gemcitabine-oxaliplatin regimen 1fludarabine phosphate 1entecavir 1eltrombopag 1deltacortene 1abivertinib 1Vincristine 1Transplantation, Autologous 1Tenofovir 1Prednisone 1Pentostatin 1Melphalan 1Interleukin-7 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Lymphoma, B-Cell × Immunotherapy, Adoptive × Clear all
NCT03598179 2019-08-07

XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
10 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell

NCT02965092 2019-05-10

CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies

Wuhan Sian Medical Technology Co., Ltd

Phase 1/2 Unknown
80 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03881774 2019-03-21

Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

Henan Cancer Hospital

Phase 1 Unknown
20 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡